UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation by Pettersen, Henrik Sahlin et al.
UNG-initiated base excision repair is the
major repair route for 5-fluorouracil in DNA,
but 5-fluorouracil cytotoxicity depends mainly
on RNA incorporation
Henrik Sahlin Pettersen, Torkild Visnes, Cathrine Broberg Va ˚gbø, Eva. K. Svaasand,
Berit Doseth, Geir Slupphaug, Bodil Kavli and Hans E. Krokan*
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology,
N-7489 Trondheim, Norway
Received March 8, 2011; Revised and Accepted June 21, 2011
ABSTRACT
Cytotoxicity of 5-fluorouracil (FU) and 5-fluoro-20-
deoxyuridine (FdUrd) due to DNA fragmentation
during DNA repair has been proposed as an alterna-
tive to effects from thymidylate synthase (TS) inhib-
ition or RNA incorporation. The goal of the present
study was to investigate the relative contribution
of the proposed mechanisms for cytotoxicity
of 5-fluoropyrimidines. We demonstrate that in
human cancer cells, base excision repair (BER)
initiated by the uracil–DNA glycosylase UNG is the
major route for FU–DNA repair in vitro and in vivo.
SMUG1, TDG and MBD4 contributed modestly
in vitro and not detectably in vivo. Contribution
from mismatch repair was limited to FU:G contexts
at best. Surprisingly, knockdown of individual
uracil–DNA glycosylases or MSH2 did not affect
sensitivity to FU or FdUrd. Inhibitors of common
steps of BER or DNA damage signalling affected
sensitivity to FdUrd and HmdUrd, but not to FU. In
support of predominantly RNA-mediated cytotox-
icity, FU-treated cells accumulated  3000- to
15000-fold more FU in RNA than in DNA.
Moreover, FU-cytotoxicity was partially reversed
by ribonucleosides, but not deoxyribonucleosides
and FU displayed modest TS-inhibition compared
to FdUrd. In conclusion, UNG-initiated BER is the
major route for FU–DNA repair, but cytotoxicity of
FU is predominantly RNA-mediated, while DNA-
mediated effects are limited to FdUrd.
INTRODUCTION
5-ﬂuorouracil (FU) and 5-ﬂuoro-20-deoxyuridine (FdUrd)
are widely used in the treatment of solid cancers, particu-
larly gastrointestinal malignancies. Most commonly used,
FU was introduced clinically ﬁve decades ago and pres-
ently some two million patients are treated each year.
However, its major cytotoxic mechanism remains
unclear and approximately one-half of the patients fail
to respond positively to FU therapy. FU is converted to
several active metabolites thought to mediate cytotoxicity
directly and indirectly by interfering with RNA and DNA
functions (1). Incorporation of 5-ﬂuorouridine triphos-
phate (FUTP) into RNA causes disruption of rRNAs
(2,3), tRNAs (4), snRNA processing (5), RNA exosome
function (6) and inhibits the conversion of uridine to
pseudouridine in RNA (7). DNA metabolism is perturbed
by 5-ﬂuoro-20-deoxyuridine monophosphate (FdUMP),
which inhibits thymidylate synthase (TS) and thereby
de novo synthesis of dTMP. This may result in imbalanced
nucleotide pools and increased incorporation of dUTP
and FdUTP into DNA (8), where FU may pair with
either A or G. Genomic uracil and FU are subject to
repair by base excision repair (BER) or mismatch repair
(MMR). BER of FU in DNA may be initiated by ﬁve
human uracil–DNA glycosylases. These are uracil-N-
glycosylase 1 and 2 (mitochondrial UNG1 and nuclear
UNG2), single-strand selective monofunctional uracil–
DNA glycosylase 1 (SMUG1), thymine–DNA glycosylase
(TDG) and methyl-binding domain 4 protein (MBD4)
(9–12). In addition, MMR can process FU:G in a
nicked plasmid in vitro and it has also been implicated in
repair FU:A base pairs (13). However, the quantitative
contribution of MMR and BER, as well as the possible
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cytotoxicity remain obscure.
Deﬁciency in DNA repair is associated with tolerance to
ﬂuoropyrimidines in several cell systems, indeed suggest-
ing a role of DNA repair in cytotoxicity. Mechanistically,
this may be explained by accumulation of BER intermedi-
ates, such as abasic sites (AP-sites) and cleaved DNA
strands that are more cytotoxic than the original base
lesion (14). Furthermore, long repair tracts produced
during MMR may be cytotoxic and mutagenic in cells
having imbalanced nucleotide pools (1,15). MMR may
also act as DNA damage sensor, inducing G2 arrest fol-
lowing FdUrd treatment (16). Consistently, a FU-tolerant
phenotype has been reported for both human and murine
cells deﬁcient in MMR (16,17). The evidence linking BER
to ﬂuoropyrimidine cytotoxicity is more ambiguous.
Mouse embryonic ﬁbroblast (MEF) knockouts of genes
encoding TDG or MBD4 display FU tolerance (18,19),
and POLb knockout MEFs showed increased tolerance
to FdUrd and other TS-inhibitors (20). Overexpression
of a dominant negative APE1 mutant in hamster CHO
cells confers 25-fold tolerance to FdUrd and 5-fold to
FU (21). In contrast, siRNA knockdown of SMUG1 in
MEFs increased sensitivity to FU while Ung
 /– MEFs and
Ung
 /– chicken B cells (DT40) were essentially identical to
wild type (22–24). As for human cancer cell lines, the ex-
pression levels of UNG was not correlated with sensitivity
to TS-inhibitors (25). Furthermore, expression of the
UNG-speciﬁc inhibitor Ugi did not affect FdUrd or FU
sensitivity (26). Also, down-regulation of POLb had no
effect on FU cytotoxicity (27). Whether non-human
MEF, CHO and DT40 cells are good models to study
the mechanism of ﬂuoropyrimidines in human cancer
cells is an open question.
In this article we analyse the relative contribution of
BER, including individual DNA glycosylases and MMR
to FU–DNA repair in human cancer cell lines. In
addition, we investigate the overall signiﬁcance of the
BER pathway in 5-ﬂuoropyrimidine cytotoxicity using
BER- and DNA damage signalling inhibitors. The cyto-
toxic mechanism of FU, FdUrd and 5-ﬂuorouridine
(FUrd) were further elucidated by quantifying FU levels
in DNA and RNA after exposure, measuring reversal
effects by normal deoxyribo- and ribo-nucleosides/
-nucleotides, and by analysing inhibition of TS. We
found that BER initiated by UNG was the major con-
tributor to FU–DNA repair in vitro and in vivo. The con-
tribution from MMR was surprisingly modest in vivo and
limited to FU:G contexts in vitro. However, BER
processes did not signiﬁcantly affect overall FU cytotox-
icity, consistent with the majority of earlier reports
(23–27). Rather, the cytotoxic mechanisms of FU may
be dominated by perturbation of RNA functions, with
DNA-mediated effects apparently limited to FdUrd.
MATERIALS AND METHODS
Cell lines, chemicals and enzymes
Human cell lines HeLa S3 (cervical adenocarcinoma),
SW480 (colon adenocarcinoma), CX-1 (colon
adenocarcinoma), HCT-8 (ileocecal adenocarcinoma),
HBL-100 (epithelial non-tumorigenic breast) and AGS
(gastric adenocarcinoma) were purchased from ATCC.
Cells were cultured in DMEM (4500mg/l glucose) with
10% FCS, 0.03% L-glutamine, 0.1mg/ml gentamicin and
2.3mg/ml fungizone at 37 C and 5% CO2. MEFs were
cultured as described (23). FU, FdUrd, FUrd, HmdUrd,
methoxyamine (MX), 4-amino-1,8-naphthalimide (4-AN),
caffeine, vanillin, nucleosides, nucleotides and oligodeox-
ynucleotides were from Sigma-Aldrich. ATM Kinase in-
hibitor (sc202963) was from Santa Cruz Biotech. siRNA
targeting UNG (Assay ID: 36376), SMUG1 (AM16708A,
ID: 21193, 140141, 21109), TDG (Assay ID: 12923),
MSH2 (siRNA ID: s8966) and MBD4 (siRNA ID:
s17077) were from Ambion. Radionucleotides were from
Perkin-Elmer. Restriction endonucleases were from New
England Biolabs. Recombinant human His-tagged APE1,
UNG2 and SMUG1 were puriﬁed as described (9,28).
Human TDG cDNA from the construct pPRS202b (10)
was subcloned into the BamHI and SalI sites of the
pET28A vector (Novagene), generating pET28a-hTDG.
His-tagged recombinant TDG protein was produced in
Escherichia coli BL21 CodonPlus (DE3)-RIPL
(Stratagene), puriﬁed using Dynabeads Talon (BD
Biosciences), and further puriﬁed by MonoQ (GE
Healthcare) chromatography.
Combined MMR and BER assay
Cultured cells were harvested by trypsination at 50–70%
conﬂuence. Nuclear extracts were prepared as described
(29). To generate a substrate for both BER and MMR,
a unique Nt.BbvCI site was introduced into the substrate
plasmid (pGEM-3Zf
+) at position 388 using the
QuickChange Site-Directed Mutagenesis Kit (Stratagene)
according to the manufacturer’s protocol, allowing gener-
ation of a nick serving as a strand selection signal for
MMR. Substrates containing FU opposite A or G for
BER and MMR were prepared essentially as described
(29). Substrate (300ng cccDNA treated with 5U
Nt.BbvCI when indicated) was incubated with 40mg
nuclear extract (TDG depleted and pre-incubated with
Ugi or neutralizing SMUG1 antibodies when indicated)
in BER buffer (29) supplemented with 250mM NAD
and 10mM of each dNTP at 37 C for indicated time
periods. Reactions were stopped by addition of 25mM
EDTA, 0.5% SDS, 150mg/ml proteinase K (ﬁnal concen-
trations) and incubation at 55 C for 30min. DNA was
puriﬁed by phenol–chloroform extraction and ethanol
precipitation using 10mg glycogen as carrier. DNA was
then treated with puriﬁed recombinant human UNG
(0.1mg/ml) (30) (U- and FU-substrates) or TDG
(0.5mg/ml) (T:G substrates), as well as 50mM MX and
0.2mg/ml RNaseA (NEB buffer 2 and 0.1mg/ml BSA) for
1h at 37 C, followed by treatment with restriction
endonucleases XmnI and HincII (5U each) for 1h.
Restriction fragments were analysed on 2% agarose gels,
stained with ethidium bromide and band intensities
were quantiﬁed using ImageJ software (http://rsb.info
.nlh.gov/ij/).
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activity assays
U, FU- and HmU-DNA excision activities were measured
using a 50-end labelled FAM or
33P-labelled 22-mer
oligodeoxynucleotide containing a centrally positioned
modiﬁed base (50-GATCCTCTAGAGT-X-GACCTGCA
-30, where X=FU, HmU or U). Excision activity by
nuclear extract (5mg) or total cell extract (10mg) was
measured using the indicated oligomer substrate, as
described (9). Glycosylases (in oligomer and BER
activity assays) were inhibited by pre-incubating the cell
extracts on ice with 0.1mg Ugi, 0.1mg neutralizing
SMUG1 antibody (PSM1) (9) and 1ml anti-TDG anti-
serum (diluted 1:3) (31) when indicated. Excision activities
by puriﬁed proteins were measured using recombinant
human His-tagged UNG2, SMUG1, or TDG, 0.1pmol
oligonucleotide substrate in UDG buffer (9) containing
50mM NaCl and 0.1pmol recombinant hAPE1 (28)
after incubation at 37 C for 30min. BER incorporation
assays were carried out in the same buffer as BER/MMR
assays, supplemented with 3mCi dCTP or dTTP
(3000Ci/mmol, Perkin-Elmer) essentially as described
(29). AP-site incision (Figure 5A) assays after
MX-treatment of AP-site-containing oligonucleotide as
substrate were carried out essentially as described (28).
UDG-activity assays using [
3H]uracil-containing calf
thymus DNA substrates were as described (9) using 3mg
whole-cell extract (Supplementary Figure S1B). Kinetic
properties of UNG2 and SMUG1 on FU:A and FU:G
oligomer substrates were examined using excess substrate
as described (28) (Supplementary Figure S1A).
Transfection with siRNA and veriﬁcation of silencing
Cells were plated in six-well dishes (150000 cells/well) in
1.6ml antibiotic-free medium and cultured overnight.
Cells were then transfected using Dharmafect
(Dharmacon) transfection agent (4ml/well) and siRNAs
dissolved in OptiMEM (Invitrogen). siRNAs targeted
SMUG1 (a mix of three siRNAs, ﬁnal concentration
30nM each), UNG (60nM ﬁnal), TDG (60nM ﬁnal),
MSH2 (100nM ﬁnal), or MBD4 (60nM ﬁnal). After
24h cells were either trypsinated and replated (for
survival assays) or incubated for another 24h in
complete medium prior to drug exposure (for survival
assays, FACS and LC/MS/MS) or harvesting (western
blots, UDG activity assays). Whole-cell extracts for veri-
ﬁcation of UDG silencing (activity assays) were prepared
48h after transfection by dissolving harvested cells in 50ml
lysis buffer [10mM Tris–HCl, pH 7.5, 200mM NaCl,
1mM EDTA, 1mM DTT, 1  Complete protease inhibi-
tor (Roche) and 0.5% NP-40] and sonication for 3 45s
at 4 C. UNG activity (3mg extract protein) was measured
by the release of [
3H]uracil from nick-translated calf
thymus DNA (U:A substrate). SMUG1 activity (10mg
extract) was measured by oligomer cleavage assays on a
U:G 22-mer in the presence of Ugi (0.1mg) and 1ml
anti-TDG antiserum (diluted 1:3). TDG activity was
measured in 10mg extract on the same oligomer substrate,
but in the presence of Ugi (0.1mg) and neutralizing
SMUG1 antibodies (PSM1) (9).
For western blot veriﬁcations of protein knock downs,
50–100mg protein in whole-cell extract was treated with
0.5ml each of Omnicleave Endonuclease (200U/ml
Epicentre Technologies), DNase (10U/ml; Roche), micro-
coccal nuclease (100–300U/mg; Sigma-Aldrich) and 1ml
RNaseA (20mg/ml; Sigma-Aldrich) for 10min at room
temperature. Extracts were then subjected to gel electro-
phoresis and western blot detection of UNG [UNG
antibody PU059 (30)], SMUG1 [PSM1 (9)], TDG
[hTDG-antiserum (31)], MSH2 [mouse monoclonal
MSH2 antibody, 3A2B8C (ab52266) (AbCam), 1:500],
MBD4 [rabbit polyclonal MBD4 antibody, ab12187,
AbCam) and b-actin (mouse monoclonal ab8226
(AbCam), 1:2000], essentially as described (9).
Survival assays after drug exposure
For continuous drug exposure assays, 2000–4000 cells/well
in 96-well culture dishes were exposed 24h after plating
(48h post-transfection for siRNA tranfected cells) and
cultured for four days with continuous drug exposure
in the presence or absence of molecular inhibitors when
indicated (MX, 4-AN, vanillin, caffeine, ATM kinase
inhibitor, ATM/ATR kinase inhibitor). For transient
exposure, 150–300 cells/well were exposed for three days,
after which medium was removed, cells washed with PBS
and allowed to grow unexposed or in the presence of the
indicated molecular inhibitors (MX, 4-AN) for seven
days. For colony formation assays, 200–4000 cells were
plated in six-well plates, exposed for three days, washed
with PBS and allowed to grow unexposed in complete
medium for seven days. Colonies larger than  20cells
were counted. For the MTT-assay, growth medium was
replaced with 100ml fresh medium containing 0.5mg/ml
MTT (Sigma), and incubated at 37 C for 4h. An
amount of 50ml of medium was subsequently removed,
100ml 2-propanol with HCl (0.1M) was added and
MTT–formazan dissolved using a mechanical shaker.
Absorption at 588nm was recorded using a Titertek
Multiscan Plus Reader.
FACS analysis of cell-cycle
At 48h post-transfection, cells were exposed to the
indicated drugs for 48h prior to harvesting by
trypsination. Cells were ﬁxed in 70% methanol, washed
twice with PBS and then treated with 50ml RNaseA
(100mg/ml in PBS) at 37 C for 30min prior to DNA
staining with 200ml propidium iodide (50mg/ml in PBS)
at 37 C for 30min. Cell-cycle analyses were performed
using a FACS Canto ﬂow cytometer (BD-Life Science).
Quantiﬁcation of FU in DNA and RNA by LC/MS/MS
Nucleic acids were isolated from ﬂuoropyrimidine-treated
cells by the DNeasy Blood and cell culture DNA isolation
kit (Qiagen) or by the mirVana RNA-isolation kit
(Ambion). DNA or RNA samples were enzymatically
hydrolyzed to nucleosides by nuclease P1, snake venom
phosphodiesterase and alkaline phosphatase as described
(32). Then 3 volumes of methanol were added and tubes
centrifuged (16000g, 30min). The supernatants were
dried and dissolved in 50ml 5% methanol in water (v/v)
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contamination by residual free FdUrd and FUrd was
excluded by running parallel control samples treated
with alkaline phosphatase only, in which no FdUrd and
FUrd were detectable. A portion of each sample was
diluted for the quantiﬁcation of the unmodiﬁed nucleo-
sides (dAdo, dCyd, dGuo, dThd, Ado, Cyd, Guo and
Urd). Chromatographic separation was performed on a
Shimadzu Prominence HPLC system with a Zorbax
SB-C18 2.1 150mm i.d. (3.5mm) column equipped with
an Eclipse XDB-C8 2.1 12.5mm i.d. (5mm) guard
column (Agilent Technologies). For FdUrd and FUrd,
the mobile phase consisted of water and methanol,
starting with a 3.5min gradient of 5–70% methanol,
followed by 1min with 70% methanol and 6.5min
re-equilibration with 5% methanol. Unmodiﬁed nucleo-
sides were chromatographed isocratically with
water:methanol:formic acid in ratio 85:15:0.1. Mass spec-
trometry detection was performed using an Applied
Biosystems/MDS Sciex 5000 triple quadrupole (Applied
Biosystems) operating in negative electrospray ionization
mode for FdUrd and FUrd, or positive electrospray ion-
ization mode for unmodiﬁed nucleosides. LC/MS/MS
chromatograms showing FdUrd in DNA and FUrd in
RNA hydrolysates are shown in the Supplementary
Figure S4.
TS assay
TS activity was measured as previously described (33) with
minor modiﬁcations. Cells were seeded in 24-well plates
(70000 cells/well) and treated with the indicated
5-ﬂuoropyrimidine for 1h. An amount of 1mCi of
[5-
3H]deoxyuridine (20Ci/mmol, Moravek Biochemicals
Inc.) was added (500ml ﬁnal volume) and incubated for
90min. The reaction was stopped by transferring 400ml
growth medium to 400ml (150mg/ml) activated charcoal
suspended in 5% trichloroacetic acid. The samples were
vortexed and centrifuged (16000g, 4 C), and 400ml
aliquots of the supernatant were counted using a liquid
scintillation counter. Values were corrected for back-
ground counts.
RESULTS
Repair of FU in DNA is mainly carried out by BER in
human cancer cell lines
In vitro studies suggest that both BER and MMR contrib-
ute to repair of FU in DNA. However, their relative con-
tribution has not been established (13). We employed a
novel plasmid assay to monitor DNA repair of FU in
nuclear extracts from human cancer cell lines. We
introduced FU opposite adenine or guanine within the
HincII (GTYRAC, Y=C/T, R=A/G) site of
pGEM-3Zf(+) generating FU:A and FU:G cccDNA sub-
strates, respectively. To distinguish between BER and
MMR we also introduced a Nt.BbvCI nicking site in the
pGEM-3Zf(+) vector, since MMR employs a nick to dis-
tinguish damaged and template strands (Figure 1A).
FU:A base pairs resembles T:A product base pairs to
such an extent that restriction enzymes are not capable
of distinguishing between them (13). However, treatment
with uracil–DNA glycosylase readily converts FU:A and
FU:G into AP-sites (AP:A and AP:G) which remain un-
processed after HincII digestion (Figure 1B). Thus, by
excising unrepaired FU from the plasmid with recombin-
ant UNG after the repair reactions and prior to HincII
digestion, we could distinguish unrepaired substrates from
repaired substrates. To validate the assay we used nuclear
extract from SW480 and veriﬁed repair of a T:G mismatch
substrate in a nick-dependent manner, consistent with an
active MMR system. The same extract under identical
assay conditions also carried out repair of a non-nicked-
U:A substrate, but this process was completely inhibited
by the UNG inhibitor Ugi, consistent with BER initiated
by UNG (Figure 1C). Thus, these substrates can be used
to measure both BER and MMR. Importantly, one or
both pathways can be speciﬁcally inactivated; BER by
directly inhibiting the initiating glycosylase(s) and MMR
by not introducing the nick that MMR is critically de-
pendent on.
Repair of FU:A in both nicked and intact cccDNA
substrates was completely inhibited by the presence of
the UNG inhibitor Ugi and anti-SMUG1 antibodies in
nuclear extracts from HeLa and SW480 (Figure 1D).
This indicates that BER is the main, possibly sole,
pathway for repair of FU:A. Surprisingly, we could not
detect any contribution from TDG on FU:A repair in
either extract. The repair of FU:G was also mainly per-
formed by BER, as most of the FU:G substrate was
repaired after 15min whether nicked or not (Figure 1E).
Inhibition of BER by adding Ugi and anti-SMUG1
antibody to a TDG-depleted extract (13) completely abol-
ished detectable repair of FU:G from the non-nicked sub-
strate, while a marked reduction was observed when using
nicked substrate. These results indicate a dominant role
for BER in repair of FU in DNA in both base pairing
contexts, with a smaller, but signiﬁcant, contribution of
MMR to FU:G repair.
Uracil–DNA glycosylase UNG is the major contributor to
FU–DNA repair in human cancer cells, while SMUG1
and TDG contribute more in mouse cells
Puriﬁed recombinant UNG2, SMUG1, TDG and MBD4
have all been reported to excise FU from DNA in vitro (9–
11,13). However, their relative importance in FU–DNA
repair in different cell types has so far not been
investigated. We analysed the contribution of uracil–
DNA glycosylases to the excision of FU from DNA in
nuclear extracts from several human cancer cell lines
(SW480, HeLa, CX-1, HCT-8, HBL-100, AGS), as well
as in wild type and Ung
 /– MEFs. Nuclear extracts were
incubated with duplex oligonucleotides with a central FU
paired with adenine (FU:A), guanine (FU:G), or as
single-stranded DNA (FU). SMUG1 and TDG activities
in the extracts were inhibited using neutralising antibodies
as described (9,31), while UNG2 activity was inhibited
with Ugi. Notably, MBD4 did not appear to be signiﬁ-
cantly involved, as inhibition of UNG2, SMUG1 and
TDG was sufﬁcient to inhibit essentially all measurable
FU excision activity in the extracts (Figure 2A and
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the major activity against all FU substrates in most
extracts from human cancer cell lines (SW480, HeLa,
CX1, HCT-8, HBL-100), while SMUG1 and TDG
activities were measurable only with the FU:G substrate
(Figure 2A and Supplementary Figure S1A). This was
corroborated by kinetic analysis of human UNG2 and
SMUG1, which revealed an almost 2-fold higher activity
(kcat/KM) of SMUG1 compared to UNG2 against FU:G
oligo substrates, while UNG had an almost 10-fold higher
FU:A activity (kcat/KM) compared to SMUG1
(Supplementary Table S1). To compare substrate prefer-
ence and speciﬁc activity, experiments with puriﬁed re-
combinant human UNG2, SMUG1 and TDG were
carried out. The results conﬁrmed that FU is substrate
for all three UDGs, with UNG2 as the most efﬁcient
enzyme on FU:A and especially on FU in a
single-stranded context, while SMUG1 was the most efﬁ-
cient enzyme on FU:G (Figure 2B and Supplementary
Figure S1D). As expected, TDG excised FU efﬁciently
from a FU:G context (Figure 2B), in accordance with
the analysis of FU-excision in nuclear extracts. A
dominant role for UNG2 in BER of FU:A was also
substantiated by assays measuring complete BER in
SW480 and HeLa extracts, since all detectable FU:A
repair activity was abolished when Ugi was added to the
nuclear extracts (Figure 2C). UNG2, SMUG1 and TDG
were all able to initiate FU:G repair, although with
varying efﬁciency.
FU accumulates in DNA after UNG knockdown,
while knockdown of MSH2, TDG and SMUG1
have minor effects
Our in vitro data from nuclear extracts suggested that FU
in DNA was predominantly repaired by BER initiated by
UNG2, SMUG1 or TDG. We therefore used siRNA
knockdown to examine the in vivo effects of these UDGs
in FU–DNA repair and in mediating overall
5-ﬂuoropyrimidine cytotoxicity. UNG, SMUG1 and
TDG excision activities were reduced 60–90% at 48h
after transfection and western blots veriﬁed knockdown
at the protein level (Figure 3A and B). The protein
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Figure 1. Repair of FU–DNA by BER and MMR in nuclear extracts.
(A) Cartoon showing the cccDNA substrate designed to measure FU:A
and FU:G repair by both BER and MMR. FU is positioned in the
HincII recognition sequence. The nicking endonuclease Nt.BbvCI
cleaves one strand 298bp 30 to the lesion, thus providing a
strand-discrimination signal for MMR. (B) Controls for validating
the repair assay. Agarose gel showing HincII+XmnI treated cccDNA
substrates containing either FU:A, T:A, FU:G or C:G in the HincII
recognition site. Distinction between substrates (FU:A, FU:G) and
products (T:A, C:G) are performed by FU excision by UNG generating
AP-sites that are uncleavable by HincII. (C) Positive controls for MMR
and BER and their inhibition. cccDNA substrate incubated with
SW480 nuclear extract (40mg), followed by treatment with recombinant
TDG (T:G) or UNG (U:A) and MX before puriﬁcation and
HincII+XmnI digestion. (D) FU:A repair by SW480 and HeLa
nuclear extracts (40mg) incubated with cccDNA (FU:A,
FU:A-nicked) substrates. Ugi and anti-SMUG1 antibodies were
added to the reactions when indicated. (E) FU:G repair by SW480
and HeLa nuclear extracts and TDG depleted nuclear extracts
incubated with cccDNA (FU:G, FU:G nicked) substrates. Ugi and
anti-SMUG1 antibodies were added to the reactions when indicated.
Graphs represent quantiﬁcations of above FU:G repair assays:
‘BER+MMR’ (FU:G nicked substrate), ‘BER’ (un-nicked FU:G sub-
strate), ‘MMR’ (FU:G nicked substrate, TDG-depleted nuclear extract
with Ugi and neutralizing SMUG1 antibody), and ‘No repair’
(un-nicked FU:G substrate and TDG-depleted nuclear extract with
Ugi and neutralizing SMUG1 antibody).
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fection. At 48h after transfection, SW480 and HeLa were
exposed to 40mM and 4mM FdUrd, respectively, and
incubated further for 24h. DNA was then isolated for
quantiﬁcation of genomic FU (FdUrd) by LC/MS/MS.
We observed a 2- to 6-fold increase in FU levels in
DNA in HeLa and SW480 UNG-silenced cells
(Figure 3C). In contrast, no signiﬁcant differences in
genomic FU were detected for SMUG1- and
TDG-silenced cells compared to control. MSH2
knockdown increased FU levels in DNA  2-fold in
SW480 cells, while insigniﬁcantly decreasing genomic
FU in HeLa cells. This was in agreement with our
in vitro results, indicating a major role of UNG in FU–
DNA repair, which apparently could not be compensated
for by other UDGs or MMR. As expected, FU (FUrd)
levels in co-puriﬁed RNA were unaffected by siRNA
knockdown (data not shown).
Knockdown of UNG, SMUG1, TDG, MBD4 or MSH2
negligibly affects overall ﬂuoropyrimidine cytotoxicity
and cell-cycle perturbations
If ﬂuoropyrimidine cytotoxicity is mediated by incorpor-
ation and/or repair of FU in DNA, sensitivity of cells to
ﬂuoropyrimidines should be altered by modulating repair
activity, in particular the quantitatively dominant UNG2.
However, knockdown of UNG, SMUG1, TDG, MBD4 or
MSH2 by siRNA did not signiﬁcantly alter the sensitivity
of the cancer cell lines after 96h exposure to FU or FdUrd
(Figure 4A, C and Supplementary Figure S5). Moreover,
the sensitivity of HeLa cells and SW480 cells to FU
were essentially similar. Conversely, SW480 cells were
far more resistant to FdUrd than HeLa cells (Figure 4A,
middle panel) suggesting that FU and FdUrd cytotox-
icity was mediated by distinct mechanisms. To distinguish
between the different cytotoxic mechanisms of FU and
its metabolites, we introduced a positive control for
the DNA-directed effects of ﬂuoropyrimidines, which
would be analogous to those reported for
5-hydroxymethyl-20-deoxyuridine (HmdUrd). HmdUrd
metabolites are readily incorporated into DNA, but not
RNA (34), and do not inhibit TS (35). HmU in DNA is in
turn excised by SMUG1, leading to DNA strand breaks
and apoptosis (9,36–39). HmdUrd therefore constitutes an
ideal positive control for the concept of DNA
repair-directed cytotoxicity. We monitored HmU-
excision in nuclear extracts from SW480, HeLa and
CX-1 and veriﬁed that SMUG1 constituted the only
detectable excision activity, as excision was abolished
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Figure 2. FU excision from DNA by human uracil–DNA glycosylases.
(A) FU excision by uracil–DNA glycosylases in nuclear extracts from
human cancer cell lines (SW480, HeLa, CX1) and MEFs. Nuclear
extracts (5mg) were pre-incubated with Ugi, neutralizing SMUG1
(aSMUG1), or neutralizing TDG (aTDG) antibodies as indicated
and assayed with double-stranded oligonucleotide substrates with FU
in FU:A or FU:G context, or in a single-stranded context (FU). U, S
and T indicate the individual activities of UNG2, SMUG1 and TDG,
respectively. (B) Varying amounts (0–1000fmol) of puriﬁed recombin-
ant hUNG2, hSMUG1 and hTDG assayed with oligonucleotide sub-
strates containing FU in different contexts (FU:A, FU:G, FU). (C)
BER incorporation assay using a cccDNA substrate containing FU
opposite A (FU:A) or G (FU:G). Nuclear extracts (10mg) from
SW480 and HeLa were pre-incubated with Ugi, neutralizing SMUG1-
(aSMUG1) and neutralizing TDG (aTDG) antibodies as indicated.
BER was detected by measuring incorporation of radio-labelled
nucleotides.
Nucleic Acids Research, 2011,Vol.39, No. 19 8435by inhibition with SMUG1 antibodies (Supplementary
Figure S1C). In accordance with this, both SW480 and
HeLa SMUG1 knockdowns were signiﬁcantly more
tolerant to HmdUrd than control cells (Figure 4A).
These results demonstrate that BER can in principle
modulate cytotoxicity of pyrimidine anti-metabolites
incorporated into DNA. The high tolerance of HeLa
cells to HmdUrd was possibly due to phosphorolysis re-
sulting in cleavage of the N-glycosylic bond in HmdUrd,
thus inhibiting its incorporation into DNA (40,41). In
agreement with this, addition of the HmU base increased
sensitivity to HmdUrd several fold (data not shown). The
differential response of knockdown cells to ﬂuoro-
pyrimidines and HmdUrd was also apparent in
cell-cycle distributions, in which HmdUrd-exposed cells
were shifted from G1/S arrest towards G2/M arrest sub-
sequent to SMUG1 knockdown, while the cell-cycle
proﬁles after FU and FdUrd treatment were apparently
unaffected by BER and MMR knockdowns (Figure 4B
and D).
A shorter two day incubation time resulted in a more
pronounced HmdUrd tolerance in SMUG1 knockdowns
(Supplementary Figure S2B), compared to four day incu-
bation (Figure 4A). This indicated that long incubation
was not suited for transient siRNA silencing of
glycosylases, as protein levels recover during the course
of the assay. Therefore, we cannot exclude the possibility
that long term effects on survival of cells permanently
deﬁcient in DNA repair proteins may be different from
those observed here. Nevertheless, the lack of effect of
glycosylase- and MSH2-knockdown on FdUrd tolerance
was conﬁrmed by CFU assays where colonies were
counted manually in six-well plates (Figure 4E and
Supplementary Figure S5).
BER and DNA damage response inhibitors affect
sensitivity to HmdUrd and FdUrd but negligibly
affect sensitivity to FU and FUrd
The inability of individual DNA glycosylase silencing
to affect cytotoxicity of ﬂuoropyrimidines could in prin-
ciple be explained by functional redundancy of the indi-
vidual uracil–DNA glycosylases. We attempted to achieve
simultaneous knockdown of UNG, TDG and SMUG1.
However, this resulted in unsatisfactory knockdown
of at least one glycosylase. To circumvent this prob-
lem we employed molecular inhibitors that target
the core BER proteins or DNA damage signalling.
Methoxyamine (MX) reacts with AP-sites and inhibits
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Figure 3. Veriﬁcation of siRNA knockdown of UNG, SMUG1, TDG
and MSH2 and their effect on FdUrd DNA incorporation. (A)
Quantiﬁcation of siRNA knockdown by western blots from whole-cell
extracts of SW480 and HeLa MSH2, UNG, SMUG1, TDG siRNA
silenced cells harvested 48h post-transfection. b-actin was used as
loading control. (B) Quantiﬁcation of glycosylase knockdown by
speciﬁc enzyme activity assays from whole-cell extracts 48h after trans-
fection. UNG excision activity was measured by the release of
[
3H]uracil from labelled calf thymus DNA (U:A substrate). SMUG1
and TDG activity were measured using a U:G oligomer substrate in the
presence of either Ugi and neutralizing TDG antibodies, or Ugi and
neutralizing SMUG1 antibodies, respectively. (C) Quantiﬁcation by
LC/MS/MS of incorporated FdUrd per nucleotide DNA after 24h
FdUrd exposure of MSH2, UNG, SMUG1 and TDG silenced SW480
(40mM) and HeLa (4mM) cells 48h after transfection. Cells were har-
vested, and DNA isolated, hydrolysed and analysed for FdUrd content.
FdUrd levels are normalized to the measured total number of normal
deoxynucleosides in each sample. The data points represent fold change
compared to control as is the mean±SD of two to four parallel
experiments.
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Figure 4. HmdUrd, FdUrd and FU survival and ﬂow cytometry of SMUG1, TDG, UNG and MSH2 siRNA knockdown cells. (A/C) HeLa and
SW480 cells were transfected with siRNA targeting (A) UNG, SMUG1, TDG, or (C) MSH2 and treated for four days with various concentrations of
HmdUrd, FdUrd or FU. Controls were mock-transfected. Survival was measured by the MTT assay. The curves are normalized to untreated cells.
Data points represent the mean±SD from at least two parallel experiments. (B) and (D) FACS analysis (cell-cycle proﬁles) of SW480 (B) UNG,
SMUG1, TDG, or (D) MSH2 siRNA knockdowns and control cells after treatment with 100mM HmdUrd, 25mM FU, or 25mM FdUrd for 48h.
(E) CFU assays in which cells, 48h post-siRNA transfection, were exposed for three days in six-well plates to 50mM (SW480) or 5mM (HeLa)
FdUrd, and subsequently washed in PBS and allowed to grow for seven days in normal medium, before staining and manual counting of colonies
(greater than  20 cells). The data represent the mean±SD of two parallel experiments normalized to the plating efﬁciency for the respective cells.
Nucleic Acids Research, 2011,Vol.39, No. 19 8437their processing by APE1 (42) while 4-amino-1,8-
naphtalimide (4-AN) is a potent inhibitor of PARP-1
polyribosylation (43) and BER (44,45). The inhibitory
effect of MX and 4-AN was conﬁrmed in vitro by APE1
activity measurements and BER incorporation assays, re-
spectively (Figure 5A and B). We also inhibited DNA
damage response proteins ATM/ATR by caffeine,
DNA-PK by vanillin, and ATM by the speciﬁc inhibitor
sc202963 (46). Inhibition of DNA damage response
proteins signiﬁcantly affected HmdUrd and FdUrd
survival, although differently in HeLa and SW480 cells
(Figure 5C). Relatively small effects were seen for FU
and FUrd in both HeLa and SW480 cells (Figure 5C),
suggesting that FU and FUrd have cytotoxic mechanisms
different from FdUrd. Consistently, while sensitivities to
HmdUrd and FdUrd were signiﬁcantly affected by BER
inhibitors (MX and 4-AN), much smaller effects were
observed for FU and FUrd (Figure 5C). 4-AN seemed
to protect the cells from HmdUrd and FdUrd cytotox-
icity, while MX increased survival after FdUrd exposure,
but severely aggravated HmdUrd cytotoxicity. To investi-
gate this further, we also carried out transient three day
exposure and seven days recovery in the presence or
absence of lower doses of MX or 4-AN for the full 10
days period. Consistent with the shorter continuous incu-
bation assays, only minor effects of MX and 4-AN were
seen after FU and FUrd treatment. Interestingly, the
initial protective effect of BER inhibitors from HmdUrd
and FdUrd cytotoxicity turned into an aggravating
effect after prolonged incubation times (Supplementary
Figure S3). This was also observed for MX on HmdUrd
and FdUrd cytotoxicity in SW480, but not in HeLa
(Supplementary Figure S3). Possibly, the initial protective
effects of inhibitors of BER and DNA damage signalling
may have turned into a cytotoxic effect after cells again
were allowed to multiply, due to replication of DNA with
accumulated damage.
Taken together, these results demonstrate that BER
intermediates are involved in HmdUrd cytotoxicity, but
contribute negligibly to the cytotoxicity of FU. As
opposed to FU and FUrd, FdUrd cytotoxicity seemed
to be mediated through DNA damage, although the
mechanism is apparently complex (Figure 5C and
Supplementary Figure S3).
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Figure 5. Effects of inhibitors of BER, ATM, ATR and DNA-PK on
survival after exposure of cells to HmdUrd, FdUrd, FU and FUrd. (A)
Inhibition of APE1 cleavage of methoxyamine-modiﬁed AP-sites. A
double-stranded oligonucleotide containing an AP-site was pre-treated
for 20min with various concentrations of MX, and then incubated with
recombinant APE1. The upper bands observed after denaturing PAGE
represent uncleaved 19-mer substrate, and the lower bands represent
cleaved products. Bottom row numbers represent quantiﬁcation of
AP-site cleavage (lower gel band) as a percentage of control for
various concentrations of MX (top row). (B) BER assay of repair of
cccDNA substrate containing a single 5-hmU:G base pair in the
presence of increasing concentrations of the PARP-1 inhibitor 4-AN.
Nuclear extracts from the SW480 cells were pre-incubated with various
concentration of 4-AN. Bands represent incorporation of [a
33P]dCTP
at the position of HmU. Bottom row numbers represent quantiﬁcation
of band signal as a percentage of control for various concentrations of
4-AN (top row). (C) SW480 and HeLa cell survival measured by the
MTT assay after four days of continuous exposure to varying concen-
trations of HmdUrd, FdUrd, FU or FUrd in the presence or absence
(black) of either 50mM MX (orange), 20mM 4-AN (green), 2mM
vanillin (blue), 2mM caffeine (red), or 10mM ATM kinase inhibitor
(violet). The curves are normalized to untreated cells in the presence of
the indicated molecular inhibitors. The data represent the mean±SD
of at least two parallel experiments.
8438 Nucleic Acids Research, 2011,Vol.39, No. 19Cytotoxicity of FUrd and FU may be mediated
predominantly through incorporation into RNA, while
FdUrd toxicity is mediated by DNA effects
Since inhibition of BER and DNA damage signalling did
not signiﬁcantly affect FU cytotoxicity, we wanted to
explore the mechanism further. We found that FU
accumulated in RNA at 3000- to 15000-fold higher
levels than in DNA after 24h FU drug exposure. While
FdUrd-exposure resulted in considerable incorporation of
FU into DNA (although lower than into RNA), incorp-
oration of FU into DNA was very low (Figure 6A).
Moreover, we found that ﬂuoropyrimidines inhibited
TS-activity in the following order for both SW480
and HeLa cells: FdUrd>FUrd>FU (Figure 6B).
TS-inhibition by FdUrd required  10
2-fold and 10
4-fold
lower concentration to achieve 50% inhibition (IC50), as
compared to FUrd and FU, respectively. While there were
small differences between the cell lines with respect to
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or SW480 cells pretreated with indicated concentrations of FdUrd, FUrd or FU. Measurements are plotted relative to the activity of untreated
samples. (C) Urd reversal of FUrd incorporation into RNA. HeLa or SW480 cells were treated with 2.5mM FUrd for 24h in the presence or absence
of Urd at indicated concentrations. RNA was isolated, hydrolysed and FUrd levels quantiﬁed by LC/MS/MS. The data represent the mean±SD of
at least two parallel measurements. (D) Effect on survival after exposure to FdUrd, FU and FUrd by concurrent treatment with various concen-
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the MTT assay after four days exposure. (E) Effect on FdUrd, FU and FUrd survival by concurrent treatment with nucleotides (dTMP, dUMP,
UMP). Increasing concentrations of nucleotides were added to SW480 or HeLa cells simultaneously treated with either FdUrd (SW480: 50mM,
HeLa: 5mM), FU (50mM), or FUrd (5mM). Survival was measured by the MTT assay after four days exposure. The survival data represent the
mean±SD of at least two parallel measurements.
Nucleic Acids Research, 2011,Vol.39, No. 19 8439TS-inhibition, the effects on cell survival were quantita-
tively very different, suggesting that at least two mechan-
isms must contribute to cytotoxicity of ﬂuoropyrimidines.
In order to distinguish the mechanisms of FdUrd-, FUrd-
and FU-cytotoxicity, thought to arise through a lack of
nucleotides and/or incorporation into nucleic acids, we
attempted to reverse cytotoxicity by supplying normal
nucleosides (dThd, dUrd, Urd) (Figure 6D and
Supplementary Figure S2A) and nucleotides (dTMP,
dUMP, UMP) (Figure 6E). We do appreciate that these
experiments can give only a broad overview, since both
cellular uptake and metabolic interconversions may be cell
line- and compound-dependent. Nevertheless, while the
cytotoxic effect of FdUrd was readily reversed by dThd
and dTMP, and partially by dUrd and dUMP, it was rela-
tively unaffected by Urd and UMP (Figure 6D, E and
Supplementary Figure S2A). This indicated a signiﬁcant
contribution of TS-inhibition to FdUrd cytoxicity. The
cytotoxic effect of high concentrations of dThd is most
likely due to its well known cell-cycle blocking effect fre-
quently exploited for cell-cycle synchronization. In
contrast, FUrd cytotoxicity was efﬁciently reversed by
Urd and UMP, but not by dUrd/dUMP or dThd/
dTMP. Consistently, we found that the reversal of FUrd
cytotoxicity by Urd was accompanied by a very strong
reduction of FU in RNA (Figure 6C). This suggests that
FUrd cytotoxicity was largely mediated through RNA in-
corporation. Interestingly, FU toxicity was also unaffect-
ed or slightly aggravated by dUrd and dThd, and, like
FUrd, reversible by Urd and UMP, though to a lesser
extent. FU cytotoxicity was slightly reversed by dTMP,
although only at concentrations  100- to 1000-fold
higher than those required for reversal by UMP. The
lack of reversibility of FU effects by dThd agrees well
with the  10
4-fold weaker TS-inhibition by FU than by
FdUrd (Figure 6B), suggesting an RNA-mediated cyto-
toxicity similar to that of FUrd.
DISCUSSION
FU is converted to different metabolites that may directly
or indirectly affect both DNA and RNA structure and
transactions (Figure 7A). We found that UNG-initiated
BER was the main contributor to DNA repair of FU
in vitro, while MMR was only active on FU:G base
pairs. UNG was the sole glycosylase in nuclear extracts
initiating repair in a FU:A context, and a major contribu-
tor in a FU:G context (Figure 2A and C). In support
of our in vitro results, UNG was the only siRNA target
that consistently caused an increase in genomic FU levels
in both cell lines (Figure 3C). Still, neither knockdown
of UNG, SMUG1, TDG, MBD4 nor MSH2 affected
overall ﬂuoropyrimidine sensitivity. In contrast, SMUG1
knockdown speciﬁcally reduced cytotoxicity of HmdUrd,
demonstrating that the concept of cytotoxicity enhance-
ment by DNA fragmentation is feasible in a ‘clean’
model case in which the phosphorylated metabolite is
incorporated into DNA, followed by base excision and
generation of strand breaks. HmdUrd has no known
RNA effects and is not converted to a TS-inhibitor
(34,35). Inhibition of the common downstream BER
steps or DNA damage signalling modulated the sensitivity
to FdUrd, indicating that BER contributes to cytotoxicity
to some extent. However, this did not depend on a single
glycosylase, suggesting that they are functionally redun-
dant in this respect. Notably, BER and DNA damage
signalling inhibitors did not modulate sensitivity to FU
or FUrd, except for a small, but signiﬁcant effect of the
PARP-1 inhibitor 4-AN. This is, however, not necessarily
BER related as PARP-1 is involved in multiple cellular
processes apart from BER (47). Indeed, earlier generation
PARP-1 inhibitors have been shown to enhance FU cyto-
toxicity at high concentrations, due to increased FU in-
corporation into RNA (48). Thus, our results are
consistent with previous reports indicating that FdUrd
cytotoxicity may be partially mediated by BER (20,21).
In contrast, BER seems not to affect FU and FUrd cyto-
toxicity signiﬁcantly.
Our results are in apparent conﬂict with a previous
study reporting that SMUG1-knockdown MEFs were
more sensitive to killing by FU and cells overexpressing
SMUG1 less sensitive, when compared with wild type
(22). We ﬁnd that SMUG1 represents the main glycosylase
activity excising FU from DNA in MEF nuclear extracts,
while UNG had a negligible role in mouse cells (Figure 2A
and Supplementary Figure S1). Thus, species differences
in FU–DNA repair may contribute to these apparently
conﬂicting results. This difference is of interest because
results from FU treatment of MEF cells are often
assumed to be valid for human cells. However, recently
published data from our laboratory indicate that such ex-
trapolations can be misleading, as there are generally sig-
niﬁcant differences in uracil excision activities between
human and mouse cell lines (49). Species differences may
also explain the discrepancy between our results and an
earlier ﬁnding that Tdg
 /– MEFs have increased tolerance
to FU, as well as the their observation of a more modest
effect of TDG knockdown in HeLa cells (18). The reported
FdUrd-resistance in UNG-silenced HeLa (50) is more dif-
ﬁcult to reconcile with our results. However, in agreement
with our results, several studies report that UNG deﬁ-
ciency (22–24), UNG inhibition (26) or UNG expression
(25) has no effect on cytotoxicity of FU, FdUrd or speciﬁc
TS inhibitors. We conclude that BER contributes only
modestly to cytotoxicity of FU in human cancer cells.
We found a clear contribution of MMR in repair in a
FU:G context in vitro, although the rate was far lower
than that of BER. We cannot exclude the possibility
that the MMR contribution is underestimated in our
in vitro assay, for example as a consequence of alternative
repair of the nicked MMR DNA substrate by a DNA
ligase. However, the modest contribution of MMR to
FU removal in intact SW480 cells and the absence of sig-
niﬁcant effect in HeLa cells after knockdown of MSH2
support our in vitro results. Furthermore, our results
and the inability of MMR proteins to recognise FU:A in
gel shift assays (13,16), indicate that MMR most likely
recognizes only FU:G mismatches. However, certain
MMR mutants deﬁcient in repair but proﬁcient in DNA
damage signalling are still able to mediate cytotoxicity of
8440 Nucleic Acids Research, 2011,Vol.39, No. 19genotoxic drugs (51). Consequently MMR might mediate
cytotoxicity of FU by mechanisms other than DNA
repair. Notably, some 10–15% of colon cancers are
MMR-deﬁcient due to inactivating mutations or epigen-
etic silencing (52). Cancer cell lines deﬁcient in the MMR
components MSH2 (17) or MLH1 (19,53) are reported to
display increased resistance to ﬂuoropyrimidines. FU re-
sistance and its correlation to microsatellite instability
(MSI) or MMR-deﬁciency has been ambiguous (54,55).
However, randomized controlled trials seem to agree
that MSI correlates with less beneﬁt from adjuvant FU
(56,57). Thus, while our experiments indicate a modest
role for MMR repair of FU in vitro and in cultured
cells, they do not exclude a signiﬁcant involvement of
MMR in the FU resistant patients. One such mechanism
could be that the MMR mutator phenotype enhances gen-
eration of FU resistant cells. An alternative possibility
may be that the fraction of FU:G compared with FU:A
is so small that its repair by MMR does not contribute
measurably to overall levels of FU in DNA, but long
repair patches generated by MMR of these quantitatively
minor lesions might still contribute to cytotoxicity. The
strongest arguments against these possibilities would be
that we could not demonstrate increased survival in
MSH2 knockdown cells (Figure 4E).
Generally, our results demonstrate that the
5-ﬂuoropyrimidine nucleosides FdUrd, FUrd and the
base FU exert their effects by quantitatively different
mechanisms, suggesting that FU was predominantly
metabolised to ribonucleotides and consequently
incorporated into RNA (Figure 7A). Thus, we found
that inhibition of TS-activity by FdUrd was achieved at
 100-fold lower concentrations than for FUrd, and inhib-
ition by FU required another  100-fold higher concentra-
tion compared with FUrd. These results and the RNA
incorporation measurements demonstrate that there is sig-
niﬁcant cross metabolism between FU, FdUrd and FUrd
(Figure 6A). In support of RNA incorporation as a major
mechanism of cytotoxicity, we observed a correlation
between cytotoxicity and RNA incorporation for all
ﬂuoropyrimidines (Figure 7B). It should be noted that
although RNA incorporation is massive compared to
DNA incorporation, we have not proven a causative rela-
tionship to cytotoxicity, merely a clear association.
Further work on the possible mechanism of cytotoxicity
from RNA incorporation would seem warranted.
However, the level of RNA incorporation associated
with a substantial decrease in survival was several fold
lower for FdUrd than for FUrd and FU, indicating that
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Figure 7. Overview of metabolism of 5-ﬂuoropyrimidines and correl-
ations between survival and RNA incorporation or TS-inhibition. (A)
Schematic overview of 5-ﬂuoropyrimidine metabolism the three main
routes to FU cytotoxicity: RNA incorporation of FUTP (red),
TS-inhibition by FdUMP (blue) and DNA incorporation of FdUTP
and dUTP (green). FdUTP incorporated into DNA end up as FU:A
(mainly) or FU:G base pairs, which are predominantly repaired by the
BER pathway initiated by UNG, with minor contributions from
SMUG1, TDG and MMR for repair of FU:G. FU and FUrd cytotox-
icity is predominantly mediated through RNA incorporation (red) and
FdUrd through dTTP depletion (blue), while misincorporated
5-FdUTP and dUTP (green) contribute negligibly to overall
5-ﬂuoropyrimidine cytotoxicity. DUT, deoxyuridine triphosphatase;
DPD, dihydropyrimidine dehydrogenase; OPRT, orotic acid
phosphoribosyl transferase; RR, ribonucleotide reductase; TK, thymi-
dine kinase; TP, thymidine phosphorylase; UK, uridine kinase; UP,
uridine phosphorylase. (B) Analysis of correlation of RNA incorpor-
ation versus survival and TS-inhibition versus survival after FdUrd,
FUrd and FU treatment. Values for FUrd RNA levels (Figure 6A
and C) or TS-inhibition {100% – [TS-activity (Figure 6B)]} are
plotted against cell survival (Figure 4) after treatment with the
nearest corresponding 5-ﬂuoropyrimidine concentration. Lines repre-
sent linear trend lines in each plot.
Nucleic Acids Research, 2011,Vol.39, No. 19 8441factors other than RNA incorporation contribute to
FdUrd cytotoxicity. It should be mentioned that FU cyto-
toxicity was slightly reversed by dTMP, although at rela-
tively high concentrations. Earlier studies on FU
cytotoxicity in other cell lines reported both reversal and
aggravation by thymidine, indicating cell-speciﬁc differ-
ences in the mechanism of cytotoxicity (58). The failure
of thymidine to reverse FU and FUrd cytotoxicity was,
however, mirrored in correlation plots of TS-inhibition
versus survival (Figure 7B), where FUrd and FU
cytotoxity was signiﬁcant even at low TS-inhibition
levels. Again, this suggests mechanisms of action other
than TS-inhibition for FUrd and FU. In accordance
with this, in a comprehensive drug activity gene expression
study, FU clustered with RNA synthesis inhibitors, sug-
gesting that a major mechanism of action is RNA-directed
(59). Finally, microarray proﬁling of FU resistant cell lines
tend not to ﬁnd BER genes to be differentially regulated,
as one might expect if BER were an important mediator of
cytotoxicity (60–63).
In conclusion, we ﬁnd that cytotoxicity from excision
repair, whether BER or MMR, contributes only in a
minor way to the mechanism of action of FU.
Furthermore, the cytotoxic contribution from BER of
FU–DNA would be limited to FdUrd, which is less
commonly used in the clinic. TS-inhibition also seems to
contribute substantially to the mechanism of FdUrd, but
the dominant mechanism of FU cytotoxicity seems to be
more closely associated with RNA incorporation.
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